Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$2.33 - $5.07 $77,835 - $169,368
-33,406 Reduced 19.56%
137,376 $326,000
Q2 2023

Aug 11, 2023

BUY
$4.67 - $6.55 $224,122 - $314,347
47,992 Added 39.08%
170,782 $818,000
Q1 2023

May 10, 2023

BUY
$4.95 - $6.09 $133 - $164
27 Added 0.02%
122,790 $696,000
Q4 2022

Feb 13, 2023

BUY
$5.09 - $9.05 $31,272 - $55,603
6,144 Added 5.27%
122,763 $687,000
Q3 2022

Nov 10, 2022

BUY
$3.5 - $7.2 $91,910 - $189,072
26,260 Added 29.06%
116,619 $749,000
Q2 2022

Aug 12, 2022

BUY
$2.7 - $7.62 $9,536 - $26,913
3,532 Added 4.07%
90,359 $309,000
Q1 2022

May 16, 2022

BUY
$6.3 - $8.84 $23,776 - $33,362
3,774 Added 4.54%
86,827 $618,000
Q4 2021

Feb 14, 2022

BUY
$6.02 - $11.43 $220,325 - $418,326
36,599 Added 78.79%
83,053 $692,000
Q3 2021

Nov 12, 2021

BUY
$5.46 - $22.6 $19,896 - $82,354
3,644 Added 8.51%
46,454 $323,000
Q2 2021

Aug 16, 2021

SELL
$18.46 - $24.36 $94,201 - $124,309
-5,103 Reduced 10.65%
42,810 $1.02 Million
Q1 2021

May 14, 2021

SELL
$17.66 - $28.92 $1.21 Million - $1.98 Million
-68,605 Reduced 58.88%
47,913 $987,000
Q4 2020

Feb 12, 2021

BUY
$23.25 - $37.73 $2.71 Million - $4.4 Million
116,518 New
116,518 $2.85 Million
Q2 2018

Aug 14, 2018

SELL
$6.91 - $9.55 $97,285 - $134,454
-14,079 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$7.34 - $11.16 $26,394 - $40,131
3,596 Added 34.3%
14,079 $103,000
Q4 2017

Feb 14, 2018

SELL
$9.15 - $12.64 $95,013 - $131,253
-10,384 Reduced 49.76%
10,483 $106,000
Q3 2017

Nov 14, 2017

BUY
$12.81 - $16.85 $123,155 - $161,995
9,614 Added 85.43%
20,867 $334,000
Q2 2017

Aug 14, 2017

BUY
N/A
11,253
11,253 $127,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.